Skip to main content
NewslettersWatchlist

Sol-Gel Technologies Ltd(SLGL-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low0.7000
Day High0.7500
Open:0.7000
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Globe Newswire
Sol-Gel Technologies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire
Sol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire
Sol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®
Globe Newswire
Sol-Gel Technologies Announces the Commercial Availability of TWYNEO®
Globe Newswire
Sol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate Developments
Globe Newswire
Sol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MA
Globe Newswire
Sol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference
Globe Newswire
Sol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®
Globe Newswire
Sol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate Developments
Globe Newswire
Sol-Gel Technologies to Present Live at Jefferies London Healthcare Conference
Globe NewsWire
Sol-Gel Technologies to Present at Upcoming Cantor Virtual Global Healthcare Conference
Globe NewsWire
Sol-Gel Technologies to Present at Upcoming H.C. Wainwright Global Investment Conference
Globe NewsWire
Sol-Gel Technologies Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Developments
Globe NewsWire
Sol-Gel Technologies Announces FDA Approval of TWYNEO®
Globe NewsWire
Sol-Gel Technologies to Report Second Quarter 2021 Financial Results on August 4th, 2021
Globe NewsWire
Sol-Gel Announces Pipeline Update and Future Development Plans
Business Wire
Sol-Gel Technologies and Galderma Announce Exclusive Licenses for the Commercialization of EPSOLAY® and TWYNEO® in the United States
Globe NewsWire
Sol-Gel Technologies to Present at Upcoming Jefferies Healthcare Conference and Raymond James Human Health Innovation Conference
Globe NewsWire
Sol-Gel Technologies Reports First Quarter 2021 Financial Results and Corporate Update
Globe NewsWire
Sol-Gel Technologies Provides Update on FDA Review of EPSOLAY®
Globe NewsWire
Sol-Gel Technologies Reports Full Year 2020 Financial Results and Corporate Update
Globe NewsWire
Sol-Gel Technologies to Present at Upcoming 2021 Raymond James Institutional Investors Conference and H.C. Wainwright Global Life Sciences Conference
Globe NewsWire
Sol-Gel Technologies to Present at Upcoming 2021 Solebury Trout Virtual Investor Conference and H.C. Wainwright BioConnect Conference
Globe NewsWire
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Twyneo® for the Treatment of Acne Vulgaris
Globe NewsWire
Sol-Gel Technologies Reports Third Quarter 2020 Financial Results and Corporate Update
Globe NewsWire
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in November 2020
Globe NewsWire
Sol-Gel Technologies to Report Third Quarter 2020 Financial Results on November 12, 2020
Globe NewsWire
Sol-Gel Technologies Announces FDA Acceptance for Filing of New Drug Application for Epsolay® for the Treatment of Inflammatory Lesions of Rosacea
Globe NewsWire
Sol-Gel to Present at Upcoming Healthcare Investor Conferences in September
Globe NewsWire
Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii®
Globe NewsWire
Sol-Gel Technologies Reports Second Quarter 2020 Financial Results and Corporate Update
Globe NewsWire
Sol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020

Profile

Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.